Furthermore, the use of hydroxytamoxifen, an active metabolite of the estrogen antagonist TAM, reduced IGF1R expression levels and E2 and IGF2-mediated cell proliferation increase in both in vitro and in an ACC xenograft model [275]. Here, IGF2 is linked to adrenal cortex carcinoma.